Subscribe to RSS
DOI: 10.1055/s-0037-1613131
The Expression of Tissue Factor and Tissue Factor Pathway Inhibitor in Aortic Smooth Muscle Cells Is Up-regulated in Synthetic Compared to Contractile Phenotype
Supported by the Université Paul Sabatier, the Fondation de France (Recherche Médicale & Santé Publique) and Novo-Nordisk company.Publication History
Received
30 June 2001
Accepted after resubmission
11 February 2002
Publication Date:
08 December 2017 (online)
![](https://www.thieme-connect.de/media/10.1055-s-00035024/200206/lookinside/thumbnails/10-1055-s-0037-1613131-1.jpg)
Summary
Tissue factor (TF) and its specific inhibitor TF pathway inhibitor (TFPI) are produced by vascular smooth muscle cells (SMCs) in vitro and are increased in vivo in atherosclerotic compared to normal vessels. Besides local regulation of the hemostatic balance, this may be related to non-hemostatic TF/protease dependent functions such as SMC proliferation, adhesion and migration. The aim of the study was to compare the expression of both proteins between the contractile (normal adult) and synthetic (neo-intimal) SMC phenotypes.
Primary cultures of SMCs isolated from rat thoracic aorta before and 10 days after balloon injury displayed stable characteristics of the contractile and synthetic phenotype, respectively. Synthetic SMCs expressed more TF mRNA than contractile SMCs, but released excess TF in the conditioned medium, so that the cell-associated TF activity measured by a factor Xa generating assay remained similar in the two subtypes. Accordingly, cell surface thrombogenicity measured under blood flow conditions was also similar. The production and release of functional TFPI was enhanced by a factor 3 to 6 (p < 0.01) in synthetic SMCs.
A difference in the quantitative expression of TF and TFPI is a new distinctive feature of SMC phenotypes. Matrix-associated TFPI derived from synthetic SMCs may serve as an anchorage for their migration and regulate protease-activated processes during neo-intima formation.
-
References
- 1 Mann KG. Biochemistry and physiology of blood coagulation. Thromb Haemost 1999; 82 (02) 165-74.
- 2 Ruf W, Mueller BM. Tissue factor Signaling. Thromb Haemost 1999; 82 (02) 175-82.
- 3 Wilcox JN, Smith KM, Schwartz SM, Gordon D. Localization of tissue factor in the normal vessel wall and in the atherosclerotic plaque. Proc Natl Acad Sci USA 1989; 86: 2839-43.
- 4 Marmur JD, Rossikhina M, Guha A, Fyfe B, Friedrich V, Mendlowitz M, Nemerson Y, Taubman MB. Tissue factor is rapidly induced in arterial smooth muscle after balloon injury. J Clin Invest 1993; 91: 2253-59.
- 5 Hatakeyama K, Asada Y, Marutsuka K, Kataoka H, Sato Y, Sumiyoshi A. Expression of tissue factor in the rabbit aorta after balloon injury. Atherosclerosis 1998; 139: 265-71.
- 6 Schecter AD, Giesen PLA, Taby O, Rosenfield CL, Rossikhina M, Fyfe BS, Kohtz DS, Fallon JT, Nemerson Y, Taubman MB. Tissue factor expression in human arterial smooth muscle cells – TF is present in three cellular pools after growth factor stimulation. J Clin Invest 1997; 100 (09) 2276-85.
- 7 Mackman N. Regulation of the tissue factor gene. Thromb Haemost 1997; 78 (01) 747-54.
- 8 Mulder AB, Smit JW, Bom VJJ, Ruiters MHJ, Halie MR, Van der Meer J. Association of smooth muscle cell tissue factor with caveolae. Blood 1996; 88 (04) 1306-13.
- 9 Broze GJJ. Tissue factor pathway inhibitor gene disruption. Blood Coag Fibrinol 1998; 9 suppl. 1: S89-92.
- 10 Caplice NM, Mueske CS, Kleppe LS, Peterson TE, Broze GJ, Simari RD. Expression of tissue factor pathway inhibitor in vascular smooth muscle cells and its regulation by growth factors. Circ Res 1998; 83: 1264-70.
- 11 Bajaj S, Steer S, Kuppuswamy M, Kisiel W, Bajaj P. Synthesis and expression of tissue factor pathway inhibitor by serum-stimulated fibroblasts, vascular mooth muscle cells and cardiac myocytes. Thromb Haemost 1999; 82: 1663-72.
- 12 Pendurthi UR, Rao VM, Williams JT, Idell S. Regulation of tissue factor pathway inhibitor expression in smooth muscle cells. Blood 1999; 94: 579-86.
- 13 Crawley J, Lupu F, Westmuckett AD, Severs NJ, Kakkar VV, Lupu C. Expression, localization, and activity of tissue factor pathway inhibitor in normal and atherosclerotic human vessels. Arterioscler Thromb Vasc Biol 2000; 20: 1362-73.
- 14 Caplice NM, Mueske CS, Kleppe LS, Simari RD. Presence of tissue factor pathway inhibitor in human atherosclerotic plaques is associated with reduced tissue factor activity. Circulation 1998; 98: 1051-7.
- 15 Kaikita K, Takeya M, Ogawa H, Suefuji H, Takahashi K. Co-localization of tissue factor and tissue factor pathway inhibitor in coronary atherosclerosis. J Pathol 1999; 188 (02) 180-8.
- 16 Jang Y, Guzman LA, Lincoff M, Gottsauner-Wolf M, Forudi F, Hart CE, Courtman DW, Ezban M, Ellis SG, Topol EJ. Influence of blockade at specific levels of the coagulation cascade on restenosis in a rabbit atherosclerostic femoral artery injury model. Circulation 1995; 92: 3041-50.
- 17 Han X, Girard TJ, Baum P, Abendschein DR, Broze GJ. Structural requirements for TFPI-mediated inhibition of neointimal thickening after balloon injury in the rat. Arterioscler Thromb Vasc Biol 1999; 19: 2563-7.
- 18 Zoldhelyi P, McNatt J, Shelat HS, Yamamoto Y, Chen ZQ, Willerson JT. Thromboresistance of balloon injured porcine carotid arteries after local gene transfer of human tissue factor pathway inhibitor. Circulation 2000; 101: 289-95.
- 19 Frid MG, Dempsey EC, Durmowicz AG, Stenmark KR. Smooth muscle cell heterogeneity in pulmonary and systemic vessels: importance in vascular disease. Arterioscler Thromb Vasc Biol 1997; 17: 1203-9.
- 20 Bochaton-Piallat ML, Ropraz P, Gabbiani F, Gabbiani G. Phenotypic heterogeneity of rat arterial smooth muscle cell clones – implications for the development of experimental thickening. Arterioscler Thromb Vasc Biol 1996; 16: 815-20.
- 21 Orlandi A, Ehrlich HP, Ropraz P, Spagnoli LG, Gabbiani G. Rat aortic smooth muscle cells isolated from different layers and at different times after endothelial denudation show distinct biological features in vitro. Arterioscler Thromb 1994; 14: 982-9.
- 22 Capron L, Jarnet J, Heudes D, Monrose DJ, Bruneval P. Repeated balloon injury of rat aorta: a model of neointima with attenuated inhibition by heparin. Arterioscler Thromb Vasc Biol 1997; 17: 1649-56.
- 23 Xuereb JM, Sié P, Boneu B, Constans J. Up-regulation of tissue factor expression by platelet-derived growth factor in human vascular smooth muscle cells in culture – role of mitogen activated protein kinase and effects of intracellular cyclic AMP. Thromb Haemost 1997; 78: 1520-6.
- 24 Diquélou A, Dupouy D, Gaspin D, Constans J, Sié P, Boneu B, Sakariassen KS, Cadroy Y. Relationship between endothelial tissue factor and thrombogenesis under blood flow conditions. Thromb Haemost 1995; 74 (02) 778-83.
- 25 Weiser-Evans CM, Quinn BE, Burkard MR, Stenmark KR. Transient reexpression of an embryonic autonomous growth phenotype by adult carotid artery smooth muscle cells after vascular injury. J Cell Physiol 2000; 182 (01) 12-23.
- 26 Li W-G, Miller FJ, Brown MR, Chatterjee P, Aylsworth GR, Shao J, Spector AA, Oberley LW, Weintraub NL. Enhanced H2O2-induced cytotoxicity in »epithelioid« smooth muscle cells – implications for neointimal regression. Arterioscler Thromb Vasc Biol 2000; 20: 1473-9.
- 27 Pauly RR, Passaniti A, Bilato C, Monricone R, Cheng L, Papadopoulos N, Gluzband YA, Smith L, Weinstein C, Lakatta EG, Crow MT. Migration of cultured vascular smooth muscle cells through a basement membrane barrier requires type IV collagenase activity and is inhibited by cellular differentiation. Circ Res 1994; 75: 41-54.
- 28 Chan P, Patel M, Betteridge L, Munro E, Schachter M, Wolfe J, Sever P. Abnormal growth regulation of vascular smooth muscle cells by heparin in patients with restenosis. Lancet 1993; 341: 341-2.
- 29 Schecter AD, Spirn B, Rossikhina M, Giesen PLA, Bogdanov V, Fallon JT, Fisher EA, Schnapp LM, Nemerson Y, Taubman MB. Release of active tissue factor by human arterial smooth muscle cells. Circul Res 2000; 87: 126-32.
- 30 Brand K, Fowler BJ, Edgington TS, Mackman N. Tissue factor mRNA in THP-1 monocytic cells is regulated at both transcriptional and posttranscriptional levels in response to lipopolysaccharide. Molec Cell Biol 1991; 4732-8.
- 31 Giesen PLA, Fyfe BS, Fallon JT, Roque M, Mendlowitz M, Rossikhina M, Guha A, Badimon JJ, Nemerson Y, Taubman MB. Intimal tissue factor activity is released from the arterial wall after injury. Thromb Haemost 2000; 83: 622-8.
- 32 Sprecher CA, Kisiel W, Mathewes S, Foster DC. Molecular cloning, expression, and partial characterization of a second human tissue-factor pathway inhibitor. Proc Natl Acad Sci USA 1994; 91: 3353-7.
- 33 Miyagi Y, Yasumitsu H, Mizushima H, Koshikawa N, Matsuda Y, Itoh H, Hori TA, Aoki I, Misugi K, Miazaki K. Cloning of the cDNA encoding mouse PP5/TFPI-2 and mapping the gene to the chromosome 6. DNA Cell Biol 1996; 15: 947-54.
- 34 Sato Y, Asada Y, Marutsuka K, Hatakeyama K, Kamikubo Y, Sumiyoshi A. Tissue factor pathway inhibitor inhibits aortic smooth muscle cell migration induced by tissue factor/factor VIIa complex. Thromb Haemost 1997; 78: 1138-41.
- 35 Ott I, Fischer EG, Miyagi Y, Mueller BM, Ruf W. A role of tissue factor in cell adhesion and migration mediated by interaction with actin-binding protein 280. J Cell Biol 1998; 140: 1241-53.